| 1. |
- Allington, Megan L., et al.
(författare)
-
Obtaining archaeointensity data from British Neolithic pottery : A feasibility study
- 2021
-
Ingår i: Journal of Archaeological Science: Reports. - : Elsevier BV. - 2352-409X. ; 37
-
Tidskriftsartikel (refereegranskat)abstract
- There is a significant lack of geomagnetic field strength (archaeointensity) measurements for many archaeological time periods in the United Kingdom (UK). This not only makes past geomagnetic secular variation difficult to model but also limits the development of archaeointensity dating. This paper presents the first archaeointensity study on UK Neolithic material. In this study, twenty-five sherds of Neolithic Grooved Ware pottery from the Ness of Brodgar, Orkney, UK, some with direct radiocarbon dates, were subjected to a full archaeomagnetic investigation with the aim of increasing the amount of archaeointensity data for the UK. Both thermal Thellier and microwave palaeointensity experiments were used to determine which technique would be most suitable for British Neolithic pottery. Three successful archaeointensity results between 35 and 40μT were obtained using thermal Thellier method, which is consistent with the limited data available within a 15° radius and geomagnetic field model predictions from the same time. We separated the results into four different types with an intention of explaining the behaviours that determine the likelihood of achieving an acceptable archaeointensity estimate. The feasibility of obtaining geomagnetic field strength information during the UK Neolithic from ceramics has been demonstrated and the results provide a solid basis for improving our knowledge of geomagnetic secular variation during archaeological time in Britain.
|
|
| 2. |
- Padidela, Raja, et al.
(författare)
-
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
- 2021
-
Ingår i: Calcified Tissue International. - : Springer. - 0171-967X .- 1432-0827. ; 108, s. 622-633
-
Tidskriftsartikel (refereegranskat)abstract
- Changing to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved phosphorus homeostasis, rickets, lower-extremity deformities, mobility, and growth versus continuing oral phosphate and active vitamin D (conventional therapy) in a randomized, open-label, phase 3 trial involving children aged 1-12 years with X-linked hypophosphatemia. Patients were randomized (1:1) to subcutaneous burosumab or to continue conventional therapy. We present patient-reported outcomes (PROs) from this trial for children aged ≥ 5 years at screening (n = 35), using a Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire and SF-10 Health Survey for Children. PROMIS pain interference, physical function mobility, and fatigue scores improved from baseline with burosumab at weeks 40 and 64, but changed little with continued conventional therapy. Pain interference scores differed significantly between groups at week 40 (- 5.02, 95% CI - 9.29 to - 0.75; p = 0.0212) but not at week 64. Between-group differences were not significant at either week for physical function mobility or fatigue. Reductions in PROMIS pain interference and fatigue scores from baseline were clinically meaningful with burosumab at weeks 40 and 64 but not with conventional therapy. SF-10 physical health scores (PHS-10) improved significantly with burosumab at week 40 (least-squares mean [standard error] + 5.98 [1.79]; p = 0.0008) and week 64 (+ 5.93 [1.88]; p = 0.0016) but not with conventional therapy (between-treatment differences were nonsignificant). In conclusion, changing to burosumab improved PRO measures, with statistically significant differences in PROMIS pain interference at week 40 versus continuing with conventional therapy and in PHS-10 at weeks 40 and 64 versus baseline.
|
|
